Related Experiment Videos
[The therapy of chronic heart failure]
1Klinik für Innere Medizin, Karl-Marx-Universität, Leipzig.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|June 15, 1990
Summary
Digitalis glycosides are the primary choice for chronic cardiac insufficiency, particularly NYHA stage II to III. Other medications like diuretics and ACE inhibitors are used when glycosides are insufficient or in combination therapy.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic cardiac insufficiency requires a structured therapeutic approach.
- Medicamentous therapy plays a crucial role alongside general measures.
Purpose:
- To outline the rational therapeutic scheme for chronic cardiac insufficiency.
- To define the primary and secondary choices of medication for heart failure management.
Summary:
- Digitalis glycosides are the first-line treatment for latent and manifest cardiac insufficiency (NYHA stage II-III) and tachyarrhythmias.
- Diuretics are indicated for persistent insufficiency despite glycoside use.
- Angiotensin-converting enzyme (ACE) inhibitors are considered second-line agents, often in combination therapy.
Impact:
- Establishes digitalis glycosides as the cornerstone of cardiac insufficiency treatment.
- Highlights the evolving role of ACE inhibitors and the development of new inotropic agents.
- Emphasizes the importance of addressing the underlying cause of cardiac insufficiency.